{
    "abstract": "To evaluate the efficacy and safety of elinzanetant compared to placebo in patients experiencing vasomotor symptoms (VMS) associated with menopause.\nA systematic search of PubMed, Embase, and Cochrane databases identified randomized clinical trials (RCTs) comparing elinzanetant and placebo in patients with menopause-related VMS. Statistical analyses pooled mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI) using R Studio 4.3.2. Pre-specified outcomes included frequency and intensity of VMS, quality of life, and sleep disturbance.\nThis meta-analysis included three randomized clinical trials reporting data on 995 patients, with 551 receiving elinzanetant. The mean age ranged from 54.4 to 55.6\u00a0years. Elinzanetant significantly reduced VMS frequency (MD -3.09; 95\u00a0% CI -4.18 to -2.01; I\nElinzanetant reduces the frequency and intensity of VMS and enhances quality of life and sleep quality in patients with menopause-related symptoms. Its safety profile is comparable to placebo.",
    "authors": [
        {
            "affiliation": "University of Western Sao Paulo Presidente Prudente Brazil.",
            "firstname": "Milene Vit\u00f3ria Sampaio",
            "initials": "MVS",
            "lastname": "Sobral"
        },
        {
            "affiliation": "University of Miami Miami FL USA.",
            "firstname": "Paula",
            "initials": "P",
            "lastname": "Rocha"
        },
        {
            "affiliation": "Federal University of Minas Gerais Belo Horizonte Brazil.",
            "firstname": "Livia Kneipp",
            "initials": "LK",
            "lastname": "Rodrigues"
        },
        {
            "affiliation": "S\u00e3o Paulo State University Botucatu Brazil.",
            "firstname": "Abner M\u00e1cola Pacheco",
            "initials": "AMP",
            "lastname": "Barbosa"
        },
        {
            "affiliation": "S\u00e3o Paulo State University Botucatu Brazil.",
            "firstname": "Naila Camila",
            "initials": "NC",
            "lastname": "da Rocha"
        },
        {
            "affiliation": "University of Pernambuco Recife Brazil.",
            "firstname": "Clara de Andrade Pontual",
            "initials": "CAP",
            "lastname": "Peres"
        },
        {
            "affiliation": "Federal University of Para\u00edba Jo\u00e3o Pessoa Brazil.",
            "firstname": "Claudio Lucca Lima",
            "initials": "CLL",
            "lastname": "Furtado"
        },
        {
            "affiliation": "University of Western Sao Paulo Presidente Prudente Brazil.",
            "firstname": "Danieli Pereira",
            "initials": "DP",
            "lastname": "da Silva"
        },
        {
            "affiliation": "University of Western Sao Paulo Presidente Prudente Brazil.",
            "firstname": "Marina Ayabe Gomes",
            "initials": "MAG",
            "lastname": "de Moraes"
        },
        {
            "affiliation": "University of Miami Miami FL USA. Electronic address: v.alvarez5@umiami.edu.",
            "firstname": "Veronica",
            "initials": "V",
            "lastname": "Alvarez-Galiana"
        }
    ],
    "conclusions": "Elinzanetant reduces the frequency and intensity of VMS and enhances quality of life and sleep quality in patients with menopause-related symptoms. Its safety profile is comparable to placebo.",
    "copyrights": "Copyright \u00a9 2025 Elsevier B.V. All rights reserved.",
    "doi": "10.1016/j.ejogrb.2025.01.050",
    "journal": "European journal of obstetrics, gynecology, and reproductive biology",
    "keywords": [],
    "methods": null,
    "publication_date": "2025-02-08",
    "pubmed_id": "39919442",
    "results": "This meta-analysis included three randomized clinical trials reporting data on 995 patients, with 551 receiving elinzanetant. The mean age ranged from 54.4 to 55.6\u00a0years. Elinzanetant significantly reduced VMS frequency (MD -3.09; 95\u00a0% CI -4.18 to -2.01; I",
    "title": "Efficacy and safety of elinzanetant in vasomotor symptoms associated with menopause: A meta-analysis of randomized controlled trials.",
    "xml": "<Element 'PubmedArticle' at 0x788505a10540>"
}